Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.

ASCOT-LLA was stopped prematurely after a median follow-up of 3.3 years owing to highly significant benefits in favour of atorvastatin over placebo on the primary coronary endpoint.

also in 132,142 other papers

The effects of percentage change in LDL-c and C-reactive protein on CV events showed only borderline significance for LDL-c change and no association with C-reactive protein change (see Supplementary material online, Table S5 ).

also in 7,017 other papers